<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Dermatologic</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Topical ASO restores WRN function for chronic skin ulcers in Werner syndrome</title>
      <description>
        <![CDATA[Werner syndrome results from biallelic mutations in the WRN gene on chromosome 8, leading to accelerated aging symptoms. Researchers at Sumitomo Pharma Co. Ltd. have reported the development and characterization of WRN-108, a splice-switching antisense oligonucleotide (ASO) designed to induce exon 27 skipping in WRN transcripts carrying the c.3139-1G>C mutation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730187</guid>
      <pubDate>Wed, 08 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730187-topical-aso-restores-wrn-function-for-chronic-skin-ulcers-in-werner-syndrome</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Genetic-mutation-illustration.webp?t=1759498851" type="image/png" medium="image" fileSize="448572">
        <media:title type="plain">Missing puzzle piece and broken DNA chain</media:title>
      </media:content>
    </item>
    <item>
      <title>Nrf2 activator counteracts atopic dermatitis pathology</title>
      <description>
        <![CDATA[Atopic dermatitis (AD) is a chronic inflammatory skin disorder associated with increased oxidative stress. In this context, pharmacological activation of the Keap1-Nrf2 pathway, a key regulator of antioxidant and cytoprotective gene expression, has emerged as a promising therapeutic strategy to re-establish redox homeostasis and reduce inflammation in AD. Researchers from the Korea Institute of Science and Technology reported the design and preclinical characterization of a novel Nrf2 activator in models of AD.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730168</guid>
      <pubDate>Tue, 07 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730168-nrf2-activator-counteracts-atopic-dermatitis-pathology</link>
    </item>
    <item>
      <title>Simcere’s rademikibart meets phase III endpoints in atopic dermatitis </title>
      <description>
        <![CDATA[Simcere Pharmaceutical Group Ltd.’s monoclonal antibody, rademikibart (CBP-201), met the primary endpoint in a Chinese phase III study in adults and adolescents with moderate to severe atopic dermatitis. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/729969</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729969-simceres-rademikibart-meets-phase-iii-endpoints-in-atopic-dermatitis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/monoclonal-antibody-mab.webp?t=1713364043" type="image/jpeg" medium="image" fileSize="243312">
        <media:title type="plain">Monoclonal antibody illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis</title>
      <description>
        <![CDATA[Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the treatment of atopic dermatitis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730042</guid>
      <pubDate>Tue, 31 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730042-infinimmune-presents-preclinical-data-on-anti-il-22-antibody-for-atopic-dermatitis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Immune/Antibodies-blue-orange-close-up.webp?t=1774969563" type="image/jpeg" medium="image" fileSize="944048">
        <media:title type="plain">3D illustration of antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>HXN-1023 drives robust anti-inflammatory responses in atopic dermatitis models</title>
      <description>
        <![CDATA[Dysregulated type 2 immune responses are central in atopic dermatitis (AD) pathophysiology. Key cytokine IL-13 drives epidermal barrier dysfunction and inflammation, while IL-31 mediates pruritus via activation of sensory neurons. Both represent clinically validated, complementary targets addressing both inflammation and itch in AD.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730040</guid>
      <pubDate>Tue, 31 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730040-hxn-1023-drives-robust-anti-inflammatory-responses-in-atopic-dermatitis-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/dermatologic-skin-layer-regenerative.webp?t=1745258161" type="image/jpeg" medium="image" fileSize="334698">
        <media:title type="plain">Skin, tissue layer illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>NAV-242 bispecific antibody supports quarterly dosing in HS</title>
      <description>
        <![CDATA[Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by dysregulated T-cell-mediated immune responses and suboptimal outcomes with current therapies. Increased expression of OX40 and OX40L in lesional HS skin suggests a contributory role for this pathway in disease-associated inflammation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730036</guid>
      <pubDate>Tue, 31 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730036-nav-242-bispecific-antibody-supports-quarterly-dosing-in-hs</link>
    </item>
    <item>
      <title>AAD 2026: Targeted oral therapies challenge injected biologics</title>
      <description>
        <![CDATA[Data presented at the 2026 American Academy of Dermatology (AAD) meeting have put the spotlight on the arrival of target-selective oral therapies that are set to challenge injected biologics in terms of efficacy, while offering greater convenience and improving access to treatment.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729951</guid>
      <pubDate>Mon, 30 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729951-aad-2026-targeted-oral-therapies-challenge-injected-biologics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Oral-medication.webp?t=1652383335" type="image/png" medium="image" fileSize="350602">
        <media:title type="plain">Oral medication</media:title>
      </media:content>
    </item>
    <item>
      <title>Multibody TEV‘325 achieves preclinical milestone</title>
      <description>
        <![CDATA[Biolojic Design Ltd. has earned an additional milestone payment from its collaboration partner, Teva Pharmaceutical Industries Ltd., for TEV‘325 (TEV-56308, formerly BD-9), a multibody targeting IL-13 and thymic stromal lymphopoietin (TSLP) for autoimmune disease]]>
      </description>
      <guid>http://www.bioworld.com/articles/729930</guid>
      <pubDate>Thu, 26 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729930-multibody-tev325-achieves-preclinical-milestone</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/collaboration-research-milestones-illustration.webp?t=1735313933" type="image/jpeg" medium="image" fileSize="78720">
        <media:title type="plain">Illustration of a road with three destination markers</media:title>
      </media:content>
    </item>
    <item>
      <title>Kintor’s KX-826 meets phase III endpoints in alopecia  </title>
      <description>
        <![CDATA[Kintor Pharmaceutical Ltd.’s topical androgen receptor antagonist, pyrilutamide (KX-826), met the primary endpoint in a pivotal phase III trial in male androgenetic alopecia, and the company will soon file an NDA with China’s National Medical Products Administration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729893</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729893-kintors-kx-826-meets-phase-iii-endpoints-in-alopecia</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Alopecia.webp?t=1773953185" type="image/jpeg" medium="image" fileSize="1021257">
        <media:title type="plain">Alopecia - hair loss </media:title>
      </media:content>
    </item>
    <item>
      <title>Market roomy, phase II zumi to reach dosing upside Apogee in AD?</title>
      <description>
        <![CDATA[In a competitive and still-needy space where Apogee Therapeutics Inc. CEO Michael Henderson noted that “even modestly differentiated products are quickly becoming blockbusters,” his firm’s IL-13 antibody zumilokibart (zumi, APG-777) has turned up satisfying phase II data in part A of the phase II atopic dermatitis (AD) experiment called Apex in moderate to severe disease. “We’re still digesting the data,” Henderson added, pointing out that the results proved better than Apogee expected at both time intervals tested.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729808</guid>
      <pubDate>Mon, 23 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729808-market-roomy-phase-ii-zumi-to-reach-dosing-upside-apogee-in-ad</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Skin-irritation.webp?t=1764623934" type="image/jpeg" medium="image" fileSize="501928">
        <media:title type="plain">Skin irritation</media:title>
      </media:content>
    </item>
    <item>
      <title>Kintor’s KX-826 meets phase III endpoints in alopecia  </title>
      <description>
        <![CDATA[Kintor Pharmaceutical Ltd.’s topical androgen receptor antagonist, pyrilutamide (KX-826), met the primary endpoint in a pivotal phase III trial in male androgenetic alopecia, and the company will soon file an NDA with China’s National Medical Products Administration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729749</guid>
      <pubDate>Thu, 19 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729749-kintors-kx-826-meets-phase-iii-endpoints-in-alopecia</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Alopecia.webp?t=1773953185" type="image/jpeg" medium="image" fileSize="1021257">
        <media:title type="plain">Alopecia - hair loss </media:title>
      </media:content>
    </item>
    <item>
      <title>Aqilion advances AQ-128 for psoriasis</title>
      <description>
        <![CDATA[In an update on the company’s pipeline and focus, Aqilion AB announced it is advancing AQ-128 as a topical treatment for psoriasis. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/729721</guid>
      <pubDate>Thu, 19 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729721-aqilion-advances-aq-128-for-psoriasis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Dermatologic-psoriasis.webp?t=1689173235" type="image/jpeg" medium="image" fileSize="249033">
        <media:title type="plain">Close up of hand scratching arm with psoriasis patches</media:title>
      </media:content>
    </item>
    <item>
      <title>Icotyde’s in; wave of switchers to oral psoriasis Protagonist?</title>
      <description>
        <![CDATA[Awaiting the potential U.S. FDA approval of a second product this year, Protagonist Therapeutics Inc. with partner Johnson & Johnson won the go-ahead for oral peptide Icotyde (icotrokinra), an IL-23 receptor antagonist, to treat moderate to severe plaque psoriasis in adults and pediatric patients 12 and older who weigh at least 40 kg and who are candidates for systemic therapy or phototherapy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729558</guid>
      <pubDate>Wed, 18 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729558-icotydes-in-wave-of-switchers-to-oral-psoriasis-protagonist</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Icotyde.webp?t=1773867848" type="image/jpeg" medium="image" fileSize="218844">
        <media:title type="plain">Icotyde</media:title>
        <media:description type="plain">Credit: Johnson &amp;amp; Johnson</media:description>
      </media:content>
    </item>
    <item>
      <title>Kanaph, Imbiologics to kick off 2026 Korea biotech, med-tech IPOs </title>
      <description>
        <![CDATA[Two biotech and three med-tech companies are slated for Kosdaq debuts this month, signaling a potential rebound for Korea financings in 2026. Kanaph Therapeutics Inc. will open with a ₩40 billion (US$26.99 million) raise and Imbiologics Corp. will debut with ₩52 billion. Additionally, Mezoo Co. Ltd., Cosmo Robotics Co. Ltd. and Recensmedical Inc. will launch IPOs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729714</guid>
      <pubDate>Tue, 17 Mar 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729714-kanaph-imbiologics-to-kick-off-2026-korea-biotech-med-tech-ipos</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Imbiologics-CEO-Ha-Gyong-sik-hero-03-13-26.webp?t=1773432672" type="image/jpeg" medium="image" fileSize="633322">
        <media:title type="plain">Ha Gyong sik giving a presentation</media:title>
        <media:description type="plain">Ha Gyong-sik, CEO, Imbiologics</media:description>
      </media:content>
    </item>
    <item>
      <title>Kanaph, Imbiologics to kick off 2026 Korea biotech, med-tech IPOs </title>
      <description>
        <![CDATA[Two biotech and three med-tech companies are slated for Kosdaq debuts this month, signaling a potential rebound for Korea financings in 2026. Kanaph Therapeutics Inc. will open with a ₩40 billion (US$26.99 million) raise and Imbiologics Corp. will debut with ₩52 billion. Additionally, Mezoo Co. Ltd., Cosmo Robotics Co. Ltd. and Recensmedical Inc. will launch IPOs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729495</guid>
      <pubDate>Fri, 13 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729495-kanaph-imbiologics-to-kick-off-2026-korea-biotech-med-tech-ipos</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Imbiologics-CEO-Ha-Gyong-sik-hero-03-13-26.webp?t=1773432672" type="image/jpeg" medium="image" fileSize="633322">
        <media:title type="plain">Ha Gyong sik giving a presentation</media:title>
        <media:description type="plain">Ha Gyong-sik, CEO, Imbiologics</media:description>
      </media:content>
    </item>
    <item>
      <title>Enanta Pharmaceuticals presents data for KIT inhibitor EDP-978</title>
      <description>
        <![CDATA[The activation of mast cells in the lungs and skin is involved in diseases such as asthma and chronic spontaneous urticaria, where the KIT receptor tyrosine kinase is a key regulator of mast cell function.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729627</guid>
      <pubDate>Fri, 13 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729627-enanta-pharmaceuticals-presents-data-for-kit-inhibitor-edp-978</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Immune/mast-cell-histamine-illustration.webp?t=1755723604" type="image/jpeg" medium="image" fileSize="116465">
        <media:title type="plain">Illustration of a mast cell releasing histamines</media:title>
      </media:content>
    </item>
    <item>
      <title>HX-16108 holds promise for treating inflammatory skin diseases</title>
      <description>
        <![CDATA[Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has developed a bispecific antibody targeting both IL-13 and IL-31, HX-16108, with an extended half-life.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729592</guid>
      <pubDate>Wed, 11 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729592-hx-16108-holds-promise-for-treating-inflammatory-skin-diseases</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Dermatologic-atopic-dermatitis2.webp?t=1588881560" type="image/png" medium="image" fileSize="357317">
        <media:title type="plain">Skin irritation on hands</media:title>
      </media:content>
    </item>
    <item>
      <title>Kyowa Kirin discontinues rocatinlimab trials due to safety issues</title>
      <description>
        <![CDATA[Shortly after Amgen Inc. walked away from its partnership with Kyowa Kirin Co. Ltd., the Tokyo-based company said it is discontinuing all ongoing clinical trials for rocatinlimab due to safety concerns.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729583</guid>
      <pubDate>Tue, 10 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729583-kyowa-kirin-discontinues-rocatinlimab-trials-due-to-safety-issues</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Clinics/Lab-vials.webp?t=1588276131" type="image/png" medium="image" fileSize="364754">
        <media:title type="plain">Lab vials and dropper</media:title>
      </media:content>
    </item>
    <item>
      <title>Erbe recalls bursting Cryoprobes  </title>
      <description>
        <![CDATA[The U.S. FDA released an early alert March 10 regarding the rupturing or bursting of certain Erbe USA Cryoprobes when they’re activated. Meanwhile, the company is voluntarily recalling the affected Erbe Flexible Cryoprobes, which use extreme cold and cryoadhesion for procedures such as the removal of blood clots, necrotic tissue, and tissue tumors and biopsies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729623</guid>
      <pubDate>Tue, 10 Mar 2026 11:30:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729623-erbe-recalls-bursting-cryoprobes</link>
    </item>
    <item>
      <title>Earendil’s HXN‑1021 exhibits potent, extended OX40L targeting</title>
      <description>
        <![CDATA[The signaling axis orchestrated by OX40L-OX40 is a T-cell costimulatory pathway implicated in multiple autoimmune diseases, such as atopic dermatitis (AD). Antibodies targeting this pathway have proven useful at treating AD in the clinical setting. Earendil Labs recently presented data regarding HXN-1021, an anti-OX40L antibody with potent activity and extended half-life, in vivo.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729511</guid>
      <pubDate>Tue, 10 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729511-earendils-hxn1021-exhibits-potent-extended-ox40l-targeting</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Inflammatory-tissue-inflammation.webp?t=1684247889" type="image/jpeg" medium="image" fileSize="336115">
        <media:title type="plain">Art concept for inflamed human tissue</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s NMPA clears HBM-7575 to enter clinic in atopic dermatitis</title>
      <description>
        <![CDATA[Harbour Biomed Ltd. and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. have announced IND approval by China’s National Medical Products Administration (NMPA) for HBM-7575 (SKB-575) for the treatment of atopic dermatitis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729413</guid>
      <pubDate>Mon, 09 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729413-chinas-nmpa-clears-hbm-7575-to-enter-clinic-in-atopic-dermatitis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Green-and-red-bispecific-antibodies.webp?t=1741632039" type="image/jpeg" medium="image" fileSize="108053">
        <media:title type="plain">Green and red bispecific antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>Less bullish OX40 field as Kyowa bid plowed under  </title>
      <description>
        <![CDATA[The OX40-targeting mechanism pursued by drug developers around the world found itself shadowed March 3 when Kyowa Kirin Co. Ltd. gave up work with rocatinlimab, a monoclonal antibody for which hopes had risen in moderate to severe atopic dermatitis, prurigo nodularis and moderate to severe asthma.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729344</guid>
      <pubDate>Thu, 05 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729344-less-bullish-ox40-field-as-kyowa-bid-plowed-under</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/AdobeStock_532547676.webp?t=1774298801" type="image/jpeg" medium="image" fileSize="429544">
        <media:title type="plain">OX40-OX40L complex</media:title>
      </media:content>
    </item>
    <item>
      <title>Kyowa Kirin discontinues rocatinlimab trials due to safety issues</title>
      <description>
        <![CDATA[Shortly after Amgen Inc. walked away from its partnership with Kyowa Kirin Co. Ltd., the Tokyo-based company said it is discontinuing all ongoing clinical trials for rocatinlimab due to safety concerns.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729343</guid>
      <pubDate>Thu, 05 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729343-kyowa-kirin-discontinues-rocatinlimab-trials-due-to-safety-issues</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Clinics/Lab-vials.webp?t=1588276131" type="image/png" medium="image" fileSize="364754">
        <media:title type="plain">Lab vials and dropper</media:title>
      </media:content>
    </item>
    <item>
      <title>Adquey finds hatchway, still more in PDE4</title>
      <description>
        <![CDATA[The U.S. FDA clearance Feb. 20 of East Windsor, N.J.-based Acrotech Biopharma Inc.’s PDE4 inhibitor Adquey (difamilast ointment 1%) for mild to moderate atopic dermatitis brought renewed focus on the mechanism, where other drugs are already approved and more are stocking developers’ pipelines across indications.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729274</guid>
      <pubDate>Mon, 02 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729274-adquey-finds-hatchway-still-more-in-pde4</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Skin-cream-application.webp?t=1623174777" type="image/png" medium="image" fileSize="388320">
        <media:title type="plain">Woman applying skin cream to elbow</media:title>
      </media:content>
    </item>
    <item>
      <title>Ailux characterizes ALX-001 for IMIDs</title>
      <description>
        <![CDATA[Researchers from Shanghai Ailux Biotechnology Co. Ltd. have disclosed preclinical data regarding their humanized bispecific antibody ALX-001 targeting TL1A and IL-23 for the potential treatment of immune-mediated inflammatory diseases (IMIDs).]]>
      </description>
      <guid>http://www.bioworld.com/articles/729018</guid>
      <pubDate>Tue, 24 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729018-ailux-characterizes-alx-001-for-imids</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Macrophage-releasing-cytokines-illustration.webp?t=1771947007" type="image/jpeg" medium="image" fileSize="590737">
        <media:title type="plain">Illustration of macrophage releasing cytokines</media:title>
      </media:content>
    </item>
    <item>
      <title>First profit in six years positions Leo Pharma for long-awaited IPO</title>
      <description>
        <![CDATA[After 118 years as a private company, dermatology specialist Leo Pharma A/S is poised to complete an IPO after reporting a full-year net profit for the first time since 2018.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729074</guid>
      <pubDate>Wed, 18 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729074-first-profit-in-six-years-positions-leo-pharma-for-long-awaited-ipo</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Skin-exam-with-dermatoscope.webp?t=1717709526" type="image/jpeg" medium="image" fileSize="197750">
        <media:title type="plain">Skin exam with dermatoscope</media:title>
      </media:content>
    </item>
    <item>
      <title>First-in-class pan-inflammasome blocker for hidradenitis suppurativa </title>
      <description>
        <![CDATA[Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728883</guid>
      <pubDate>Mon, 16 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728883-first-in-class-pan-inflammasome-blocker-for-hidradenitis-suppurativa</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/3D-skin-layers.webp?t=1710344920" type="image/jpeg" medium="image" fileSize="148730">
        <media:title type="plain">3D rendering of skin cells and elastin with collagen layer</media:title>
      </media:content>
    </item>
    <item>
      <title>IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa</title>
      <description>
        <![CDATA[Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some signaling pathways are well defined in HS, the role of TNF-like ligand 1 (TL1A) is not well understood. A group of researchers has investigated the association of TL1A with HS, as well as its association with other cytokine networks.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728813</guid>
      <pubDate>Thu, 12 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728813-il-22-and-tl1a-a-robust-couple-for-diagnosing-hidradenitis-suppurativa</link>
    </item>
    <item>
      <title>Vidac Pharma to study HK2/VDAC-targeting approach for psoriasis</title>
      <description>
        <![CDATA[Vidac Pharma Holding plc has announced the initiation of an in vivo preclinical program to evaluate the potential of its hexokinase 2 (HK2)/voltage-dependent anion channel (VDAC)-targeting approach in psoriasis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728812</guid>
      <pubDate>Thu, 12 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728812-vidac-pharma-to-study-hk2-vdac-targeting-approach-for-psoriasis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Test-tubes_dropper2.webp?t=1588878294" type="image/png" medium="image" fileSize="437615">
        <media:title type="plain">Test tube, dropper</media:title>
      </media:content>
    </item>
    <item>
      <title>Evommune, Nektar soar on atopic dermatitis phase II data</title>
      <description>
        <![CDATA[Marking an important day for those with atopic dermatitis, shares of two biopharmas surged on clinical data suggesting new biologics are on their way to help address 40% of patients with uncontrolled disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728714</guid>
      <pubDate>Tue, 10 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728714-evommune-nektar-soar-on-atopic-dermatitis-phase-ii-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Woman-itching-wrist.webp?t=1666388233" type="image/png" medium="image" fileSize="402547">
        <media:title type="plain">Woman itching wrist</media:title>
      </media:content>
    </item>
  </channel>
</rss>
